SAN FRANCISCO (GenomeWeb) – Natera said this week that it has launched a research-use-only pan-cancer circulating tumor DNA assay for academic and biopharmaceutical customers, and will offer it through its CLIA lab next year initially as a way to monitor patients for disease recurrence and later as a way to determine whether patients will benefit from chemotherapy.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.